Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-α inhibitors

Objective. To explore the regulation of factors involved in lymphocyte trafficking in patients with rheumatoid arthritis (RA) undergoing treatment with tumour necrosis factora (TNF-a) inhibitors. Methods. We examined 14 consecutive patients with RA according to ACR criteria prior to and during treatment with TNF-a inhibitors (seven etanercept, seven infliximab) and determined disease activity using the Disease Activity Score (DAS-28). Peripheral blood mononuclear cells were isolated before and after 6 and 14 weeks of treatment and analysed immediately for CD3, CD4 and CD8, expression of chemokine receptors CXCR3 and CCR4, CD45RO phenotype and for expression of interferon c (IFN-c) and interleukin 4 (IL-4) using four-colour flow cytometry. Results. We found significant increases in CD4 and CD8 T lymphocytes expressing CXCR3 after 6 and 14 weeks. The overall proportion of T lymphocytes expressing CCR4 appeared unchanged. More than half of peripheral CD4 T lymphocytes showed a memory phenotype (CD45RO), with a non-significant increase under TNF-a inhibition. Upon activation, up to 30% of CXCR3 þ /CD4 T cells expressed IFN-c, while IL-4-expressing cells were rare. There was a robust negative correlation between CXCR3 þ /CD4 T lymphocytes and DAS-28. Conclusions. TNF-a inhibition with infliximab and etanercept results in sustained accumulation of CXCR3 positive T lymphocytes in the peripheral blood of RA patients. This suggests altered lymphocyte trafficking during TNF-a inhibition.